Analyst Update: AcelRx Pharmaceuticals, Inc., AVEO Pharmaceuticals, Inc., and Twitter, Inc.

Analysts adjusted their ratings on AcelRx Pharmaceuticals Inc (ACRX), AVEO Pharmaceuticals, Inc. (AVEO), and Twitter Inc (TWTR)

by Griffin Kruse

Published on Mar 9, 2015 at 12:15 PM
Updated on Apr 20, 2015 at 5:32 PM

Analysts are weighing in today on drugmakers AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) and AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), as well as microblogging platform Twitter Inc (NYSE:TWTR). Here's a quick look at today's brokerage notes on ACRX, AVEO, and TWTR.

  • Prior to the release of ACRX's fourth-quarter earnings data tonight, the stock is swimming in the red after the U.S. Food and Drug Administration (FDA) requested more data on pain drug Zalviso. As a result, Canaccord Genuity cut its price target on the security to $6 from $8 while underscoring its "hold" rating. At last check, the shares of AcelRx Pharmaceuticals Inc are down 34% at $5.77, and earlier touched a nearly two-year low of $5.07. Year-to-date, the struggling stock is down 13.8%. Prior to today's drop, bearish sentiment in the options pits was ramping up, as ACRX's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.32 sits in the 82nd percentile of its annual range. What's more, over 41% of the stock's available float is sold short, which would take over 32 sessions to cover, at average trading volumes.

  • RBC upgraded its opinion of AVEO this morning, hiking its price target to $3 from $2 and its rating to "sector perform" from "underperform." In response, the shares are up 8.7% to hit $1.63, adding to a 94% year-to-date gain. In fact, the stock touched a two-year peak of $2.02 on Friday, thanks to promising data on its tivozanib drug. Not surprisingly, sentiment in the equity's options pits is bullish, as AVEO's 50-day ISE/CBOE/PHLX call/put volume ratio of 43.42 sits in the 78th percentile of its annual range.

  • Earlier today, Cannacord Genuity released an upbeat investment thesis of TWTR, saying, "We believe Twitter stock is mid-way through a process of winning back investors after a rough end to 2014," and waxed optimistic on the stock's 2015 prospects. On the charts, the shares of Twitter Inc have added 1.7% today to hit $47.56, contributing to a 32.6% year-to-date gain. In conjunction with TWTR's technical breakout, sentiment in the options pits is nearing an optimistic climax. Specifically, TWTR's 10-day ISE/CBOE/PHLX call/put volume ratio of 3.77 sits just 4 percentage points away from the highest similar reading taken over the past year.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Nevada Discovery That Could Jeopardize Chinese Dominance
Click to continue to advertiser's site.
Puts Popular as GM Stock Rallies
GM puts are all the rage lately
JetBlue Stock Surging Despite Sector Skepticism
J.P. Morgan Securities downgraded JBLU to "neutral" from "overweight"
The Nevada Discovery That Could Jeopardize Chinese Dominance
Click to continue to advertiser's site.